Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01821612 · ClinicalTrials.gov registry record · Early Phase 1
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer
A Early Phase 1 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 23
- Enrollment target
NCT01821612 is a Early Phase 1 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 23 participants.
The verdict
NCT01821612, a Early Phase 1 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This pilot clinical trial studies combination chemotherapy and radiation therapy before surgery followed by gemcitabine hydrochloride in treating patients with pancreatic cancer. Drugs used in chemotherapy, such as oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery.
Interventions
- DRUG 5-fluorouracil
- DRUG oxaliplatin
- DRUG leucovorin
- DRUG capecitabine
- DRUG irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-05-29 |
| Est. Completion | 2018-06-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01821612
The ClinicalTrials.gov registry entry for NCT01821612 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 5-fluorouracil is the first listed.
NCT01821612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01821612 about?
NCT01821612 is a clinical study titled "Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer". This pilot clinical trial studies combination chemotherapy and radiation therapy before surgery followed by gemcitabine hydrochloride in treating patients with pancreatic cancer. Drugs used in chemotherapy, such as oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, and gemcitab...
What is the current status of trial NCT01821612?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 23 participants. The study started on 2013-05-29. Estimated completion is 2018-06-15.
What interventions are being tested in trial NCT01821612?
The interventions under investigation include: 5-fluorouracil (DRUG), oxaliplatin (DRUG), leucovorin (DRUG), capecitabine (DRUG), irinotecan (DRUG).
Who is sponsoring clinical trial NCT01821612?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.